Using RNAseq data from AML cells with an internal tandem duplication <i>FLT3</i> mutation (<i>FLT3</i>-ITD) under six drug treatment conditions including quizartinib and dexamethasone, we identified seven distinct gene programs representing diverse biological processes involved in AML drug-induced changes. This evidence concerns the gene FLT3 and acute myeloid leukemia.